NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).

被引：0
|
作者：
Galanis, E
Buckner, JC
Maurer, M
Ballman, K
Hidalgo, M
Kreisberg, JI
Boni, J
James, CDD
Jenkins, RB
Walsh, DJ
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] UTHSCSA, San Antonio, TX USA
[4] N Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1503
引用
收藏
页码：107S / 107S
页数：1
相关论文
共 50 条
  • [31] PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Chang, Susan
    Kuhn, John
    Lamborn, Kathleen
    Robins, H. Ian
    Yung, Alfred
    Gilbert, Mark R.
    Cloughesy, Timothy
    Lieberman, Frank
    DeAngelis, Lisa
    Abrey, Lauren
    Drappatz, Jan
    Kesari, Santosh
    Dancey, Janet
    Prados, Michel D.
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [32] PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Kuhn, John
    Chang, Susan
    Lamborn, Kathleen
    Robbins, Hi
    Cloughesy, Timothy
    Lieberman, Frank
    Mehra, Minesh
    Gilbert, Mark
    Cooper, Josh
    Drappatz, Jan
    Kesari, Santosh
    Norden, Andrew
    Groves, Morris
    Aldape, Kenneth
    Yung, W. K. Alfred
    Dancey, Janet
    Prados, Michael
    NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [33] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.
    Oza, AM
    Elit, L
    Biagi, J
    Gotlieb, W
    Tonkin, KS
    Tsao, M
    Hedley, D
    Hansen, C
    Dancey, J
    Eisenhauer, E
    Seymour, L
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
  • [34] Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
    Hofmeister, Craig C.
    Yang, Xiaoxia
    Pichiorri, Flavia
    Chen, Ping
    Rozewski, Darlene M.
    Johnson, Amy J.
    Lee, Seungsoo
    Liu, Zhongfa
    Garr, Celia L.
    Hade, Erinn M.
    Ji, Jia
    Schaaf, Larry J.
    Benson, Don M., Jr.
    Kraut, Eric H.
    Hicks, William J.
    Chan, Kenneth K.
    Chen, Ching-Shih
    Farag, Sherif S.
    Grever, Michael R.
    Byrd, John C.
    Phelps, Mitch A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3427 - 3434
  • [35] Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, S.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Quinn, J. A.
    Gururangan, S.
    Egorin, M. J.
    Salvado, A. J.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Puduvalli, Vinay K.
    Giglio, Pierre
    Groves, Morris D.
    Hess, Kenneth R.
    Gilbert, Mark R.
    Mahankali, Srikanth
    Jackson, Edward F.
    Levin, Victor A.
    Conrad, Charles A.
    Hsu, Sigmund H.
    Colman, Howard
    de Groot, John F.
    Ritterhouse, MeLesa G.
    Ictech, Sandra E.
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2008, 10 (02) : 216 - 222
  • [37] Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Chapman, W.
    Tsao, M.
    Hedley, D.
    Hansen, C.
    Dancey, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 121S - 121S
  • [38] NCCTG phase II trail of bevacizumab in combination with sorafenib in recurrent GBM
    Galanis, E.
    Jaeckle, K. A.
    Anderson, S.
    Kaufmann, T. J.
    Uhm, J. H.
    Giannini, C.
    Kumar, S.
    Northfelt, D. W.
    Flynn, P. J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Irradiation enhances mammalian target of rapamycin (mTOR)-targeted glioblastoma therapy with CCI-779 (temsirolimus)
    Weiler, M.
    Pfenning, P-N
    Thiepold, A-L
    Jestaedt, L.
    Berger, B.
    Combs, S.
    Bendszus, M.
    Wick, W.
    ONKOLOGIE, 2010, 33 : 60 - 60
  • [40] Phase I and pharmacological study of CCI-779, a cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Adjei, A
    Hammond, L
    Galanis, E
    Edwards, T
    Burton, J
    Boni, J
    Tolcher, A
    Dukart, G
    Buckner, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4548S - 4549S
12345